





















All data generated or analyzed for this study are included in the published article.

### Competing interests

The authors have no conflict of interest to declare. All coauthors have seen and agree with the contents of the manuscript, and there is no financial interest to declare.

**Funding:** Not applicable.

**Author contributions:** ST: Collecting patient data and statistical analysis and genomic analysis.

YK: Writing the paper, acquisition of data, and analysis and interpretation of data.

YH: Genomic analysis.

HA, Y. M, H. A., H. O., Y. S., H. M.: Acquisition of data.

SM: Conception and design of the study.

MO: Conception and design of the study and final approval of the submitted version.

**Acknowledgements:** Not applicable

### Reference

1. Timmer A, Patton PH, Chande N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev* (2016): Cd000478.
2. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. *N Engl J Med* 362 (2010): 1383-1395.
3. Singh S, Feuerstein JD, Binion DG, et al. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. *Gastroenterology* 156 (2019): 769-808.
4. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. *Ann Intern Med* 111 (1989): 641-649.
5. Yang SK, Hong M, Baek J, et al. A common missense variant in *NUDT15* confers susceptibility to thiopurine-induced leukopenia. *Nat Genet* 46 (2014): 1017-1020.
6. Kojima Y, Hirotsu Y, Omata W, et al. Influence of *NUDT15* variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. *World J Gastroenterol* 24 (2018): 511-518.
7. Coenen MJH, de Jong DJ, van Marrewijk CJ, et al. Identification of Patients With Variants in *TPMT* and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. *Gastroenterology* 149 (2015): 907-917.
8. Akiyama S, Matsuoka K, Fukuda K, et al. Long-term effect of *NUDT15* R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine. *J Gastroenterol Hepatol* 34 (2019): 1751-1757.
9. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 55 (2006): 749-753.
10. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. *Lancet* 380 (2012): 1606-1619.
11. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* 70 (1976): 439-444.
12. Hirotsu Y, Nakagomi H, Sakamoto I, et al. Detection of *BRCA1* and *BRCA2* germline mutations in Japanese population using next-generation sequencing. *Mol Genet Genomic Med* 3 (2015): 121-129.
13. Sakamoto I, Hirotsu Y, Nakagomi H, et al. *BRCA1* and *BRCA2* mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer. *Cancer* 122 (2016): 84-90.
14. Hirotsu Y, Nakagomi H, Amemiya K, et al. Intrinsic *HER2* V777L mutation mediates resistance to trastuzumab in a breast cancer patient. *Med Oncol* 34 (2017): 3.
15. Hirotsu Y, Nakagomi H, Sakamoto I, et al. Multigene panel analysis identified germline mutations of DNA repair genes in breast and ovarian cancer. *Mol Genet Genomic Med* 3 (2015): 459-466.
16. Wusk B, Kullak-Ublick GA, Rammert C, et al. Thiopurine S-methyltransferase polymorphisms: efficient screening method for patients considering taking thiopurine drugs. *Eur J Clin Pharmacol* 60 (2004): 5-10.
17. Moriyama T, Nishii R, Perez-Andreu V, et al. *NUDT15* polymorphisms alter thiopurine metabolism and hematopoietic toxicity. *Nat Genet* 48 (2016): 367-373.
18. Kakuta Y, Naito T, Onodera M, et al. *NUDT15* R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. *Pharmacogenomics J* 16 (2016): 280-285.
19. Maeda T, Sakuraba H, Hiraga H, et al. Long-term efficacy and tolerability of dose-adjusted thiopurine treatment in maintaining remission in inflammatory bowel disease patients with *NUDT15* heterozygosity. *Intest Res* 20 (2021): 90-100.

**Citation:** Shotaro Tsunoda, Yuichiro Kojima, Yosuke Hirotsu, Hiroyuki Amano, Yuko Miura, Hiroshi Ashizawa, Hiroshi Ohyama, Kenji Hosoda, Yoji Suzuki, Hitoshi Mochizuki, Shin Maeda, Masao Omata. Influence of *NUDT15* Genotyping on Dose Intensity of Thiopurine Administration and Long-Term Clinical Outcomes (Hospitalization and Surgery). *Archives of Clinical and Biomedical Research*. 8 (2024): 10-19.